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Abstract
Nitric oxide is a cell signaling molecule that can be a potent inducer of cell death in cancers at
elevated concentrations. Nitric oxide molecules are short-lived in vivo; therefore, NO-donating
prodrugs have been developed that can deliver NO to tissues at micromolar concentrations.
However, NO is also toxic to normal tissues and chronic exposure at low levels can induce tumor
growth. We have designed a polymeric carrier system to deliver nitric oxide locoregionally to
tumorigenic tissues. A highly water solubility and biodegradable 4-arm polymer nanocarrier, sugar
poly-(6-O-methacryloyl-D-galactose), was synthesized using MADIX/RAFT polymerization, and
utilized to deliver high concentrations of nitric oxide to xenografts of human head and neck
squamous cell carcinoma (HNSCC). The in vitro release of the newly synthesized nitric oxide
donor, O2-(2,4-dinitrophenyl) 1-[4-(2-hydroxy)ethyl]-3-methylpiperazin-1-yl]diazen-1-ium-1,2-
diolate and its corresponding multi-arm polymer-based nanoconjugate demonstrated a 1- and 2.3-
fold increase in half-life, respectively, compared to the release half-life of the nitric oxide -donor
prodrug JS-K. When administered to tumor-bearing nude mice, the subcutaneously injected multi-
arm polymer nitric oxide nanoparticles resulted in 50% tumor inhibition and a 7-week extension
of the average survival time, compared to intravenous JS-K therapy (nitric oxide nanoparticles:
CR=25%, PR=37.5%, PD=37.5%; JS-K: PD=100%). In summary, we have developed an effective
nitric oxide anti-cancer chemotherapy that could be administered regionally to provide the local
disease control, improving prognosis for head and neck cancers.
1. Introduction
The clinical outcomes and overall survival rates for advanced HNSCC have not improved
significantly over the past two decades despite advancements in surgery and treatment, so
that HNSCC continues to affect over a half million new patients worldwide each year [1].
Moreover, the current therapies for head and neck cancer result in numerous adverse effects,
some permanent such as possible loss the salivary gland function and muscle control in the
shoulders. Thus, there is a clear need for less damaging therapies for head and neck cancer
that will achieve a more favorable clinical outcome and reduce treatment morbidity [2].
Nitric oxide is a cell signalling molecule involved in many mammalian physiological
processes and pathological conditions. The effects of nitric oxide on tissues are highly
concentration dependent. Low levels of nitric oxide synthase (NOS) overexpression in
cancer cells is frequently associated with enhanced tumor cell invasion and growth [3, 4]
and an increase in aerobic glycolysis capacity[5], i.e. the Warburg effect. However, high
concentrations of nitric oxide can inhibit NF-kB activity, which regulates cell proliferation,
and downregulating Bcl-xL expression, which modulates apoptotic pathways [6, 7]. Nitric
oxide has been shown to radiosensitize cancers, inhibit DNA repair mechanisms, inhibit
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hypoxia-induced drug resistance, and reverse the epithelia to mesenchyma phenotype
transition of tumors [8–10]. Nitric oxide has a halflife of about 5 s in vivo, due to rapid
reaction of the unpaired electron with hemoglobin and heme ferrous iron and subsequent
decomposition into nitrate [11]. Therefore, nitric oxide donating prodrugs have been
developed for anti-cancer therapy, such as JS-K [12].
The potential for dose-dependent carcinogenicity of nitric oxide-releasing agents has limited
their development as systemically administered anti-cancer agents. The effective and safe
use of these agents requires that the nitric oxide release be highly confined to tumorigenic
tissues and exposure to sub-therapeutic doses must be minimized. The tissue distribution of
small molecule drugs is typically non-specific, with increased exposure in clearance organs,
such as the kidneys and liver. To overcome this challenge, a drug molecule may be
conjugated to a targeted delivery system so that it will be preferentially released in
tumorigenic cells. Water-soluble polymers have been utilized for the preparation of drug
conjugates that display significant advantages in pharmaceutical applications, including low
toxicity, excellent water solubility, and tissue targeting through passive (e.g. enhanced
permeation and retention effect) or receptor-based targeting [13]. Despite the targeted nature
of these carriers in intravenous applications, healthy tissues will still receive substantial
exposure due to long residence in the clearance organs and circulatory system. Our group
and others have partially overcome this problem by delivering nanoconjugates directly to the
primary tumor and the draining lymphatics [14–21]. This approach can greatly improve the
response in locally advanced cancers, since the nanoconjugate and method of administration
can confine the drug to only the tumor and the lymph nodes draining the tumor. An issue in
the design of these drug delivery systems is the carrier must be very stable within the
extravascular space, which limits the use of micelles and liposomes, and it should be under
50 nm in size for rapid clearance from the injection site. Structured polymers such as
dendrimers meet these requirements [22–25], but dendrimers such as PAMAM constructs
are not biodegradable and have limited capacity for water-insoluble drugs. Multi-arm or star
polymers are branched nanoscale materials that have a compact structure, globular shape,
and large surface area that make them highly suited for targeted drug delivery when built
with biocompatible or biodegradable polymers.
Multi-arm polymers can be synthesized under a broad range of conditions with low
polydispersity using reversible addition-fragmentation chain transfer polymerization
(RAFT). During the RAFT process, the polymers derived keep their “livingness” so that it is
possible to prepare well defined polymers. Moreover, The RAFT process is tolerant toward
a range of functional groups thus minimizing the need for additional synthetic pathways to
install protecting groups on the monomers being used.
In this study, we report the synthesis of a new type of 4-arm sugar-decorated polymer
(Figure 1) using MADIX/RAFT polymerization and four nitric oxide-releasing analogues
based on JS-K. These conjugates were found to release nitric oxide over several hours,
which slowed the growth of tumor cells in vitro. We then demonstrated that these NO-
releasing nanoconjugates can significantly retard the growth of HNSCC xenografts in vivo
and improved the survival of animals with locally advanced disease with no apparent
systemic toxicities.
2. Materials and methods
2.1 Materials
Unless noted otherwise, all reagents and solvents were purchased from Sigma Aldrich and
used without further purification. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra
were collected on a Bruker DRX 400 spectrometer using compounds dissolved in CDCl3,
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MeOD or D2O. Chemical shifts were referenced to δ7.28 and 77.0 ppm for 1H-NMR
and 13C-NMR spectra, respectively. High-resolution mass spectrometry (HRMS) data were
generated after flow injection analysis (FIA) manually matching peaks on an Applied
Biosystems Mariner TOF spectrometer with a turbo-ionspray source. The Griess Reagent kit
was purchased from Promega Corporation (Madison, WI). Cell culture media were
purchased from Fisher Scientific (Pittsburgh, PA).
2.2 Synthesis
2.2.1 Synthesis of MADIX/RAFT agent—The MADIX/RAFT agent was synthesized
based on the procedure reported previously (Scheme 1) [26]. Pentaerythritol was used as the
starting material to react with 2-bromopropionyl bromide and O-ethylxanthic acid
(potassium salt) successively to form a four-arm sulfur compound which was used as the
MADIX/RAFT initiator agent.
Reaction of the 4-arm core with 2-bromopropionyl bromide: Pentaerithol (1.36 g, 10
mmol) was dissolved in 25 mL of dry chloroform and 2.5 mL of pyridine and cooled to 0
°C. The 2-bromo propionyl bromide (10.01 g, 45 mmol) was added dropwise, and the
reaction proceeded at ambient temperature (ca. 23°C) for 48 hours. The mixture then was
neuralized with aqueous HCl (10 wt %). Then the organic phases were washed with water,
sodium bicarbonate solution (5 %) and brine, followed by drying with sodium sulfate.
Evaporation of the solvent under reduced pressure yielded the desired compound, and the
molecular structure was verified by 1H-NMR and compared with the reported data.
Reaction of bromide intermediate with O-ethylxanthic acid (potassium salt): A solution
of the intermediate compound (2.028 g, 3.0 mmol) in chloroform (45 mL) was treated with a
10-fold excess of O-ethylxanthic acid, potassium salt (5.01 g, 30 mmol). The mixture was
stirred at ambient temperature for 3 days, and the resulting suspension was filtered and
washed with chloroform. Evaporation of the solvent followed by purification through a flash
column on silica gel using 3:7 ethyl acetate:hexanes as eluents yielded the desired
compound, and the molecular structure was verified by 1H-NMR and compared with the
reported data.
Synthesis of 1,2;3,4-di-O-isopropylidene -6-O-acryloyl-α-D-galactopyranose (AIpGP):
The RAFT agent was synthesized according to the procedure of Ting et al (Scheme 2) [27].
Briefly, to a 100-mL round bottom flask were added 1,2,3,4-di-O-isopropylidene-6-O-
acryloyl-α-D-galactopyranose (1.39 g, 5.20 mmol), basic alumina (2.44 g, 23.92 mmol), 20
mL of dry acetonitrile, and acryloyl chloride (2.26 mL, 27.04 mmol), dropwise. After
stirring under argon for 3 days at ambient temperature, the mixture was filtered through a
thin layer of celite, and the solids were washed with 50 mL of acetonitrile. The combined
organic layers were concentrated under reduced pressure. The resulting pale yellow residue
was purified through a flash column using 1:2 ethyl acetate:hexanes as eluents, and its
molecular structure was verified by 1H-NMR and compared with the reported data.
2.2.2 Synthesis of a 4-arm sugar multi-arm polymer
Synthesis of poly-(1,2:3,4-di-O-isopropylidene-6-O-methacryloyl-α-D-galactopyranose)
with the MADIX/RAFT agent: The 1,2,3,4-di-O-isopropylidene-6-O-acryloyl-α-D-
galactopyranose (3.11 g, 9.9 mmol) was treated with basic alumina and 10 mL of dry α, α,
α- trifluorotoluene in a 50-mL round bottle flask. The RAFT agent (0.054 g, 0.0622 mmol)
was added to the solution, followed by the addition of AIBN (1.36 mg, 0.00827 mmol), and
the reaction flask was placed on ice and purged with argon for 30 min. The flask was then
transferred to a thermostatic oil bath at 70 °C for ca. 10 hrs. The mixture was cooled in an
ice bath and poured into cold diethyl ether to obtain the precipitate followed by
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concentration under reduced pressure (Scheme 3). The molecular structure and molecular
weight of the resulting polymer were determined by 1H-NMR and size exclusion
chromatography (SEC), respectively.
Synthesis of multi-arm poly-(6-O-methacryloyl-D-galactose): The poly-(1,2:3,4-di-O-
isopropylidene-6-O-methacryloyl-α-D-galactopyranose) (500 mg) was dissolved in 100 mL
of 90% formic acid. The solution was stirred at 60 °C for 24 hours. The solution then was
dialyzed (10 kDa tubing, Pierce, Rockford, IL) against distilled water for 2 days with water
changes every 6 hours to remove the acid. After dialysis, the resulting polymer was
lyophilized to obtain the desired multi-arm poly-(6-O-methacryloyl-D-galactose) (Scheme
3).
2.2.3 Modification of multi-arm poly-(6-O-methacryloyl-D-galactose) with
succinic anhydride—Polymers with increasing degrees of succination (20%, 40%, 60%
and 90%) were generated by reacting the star poly-(6-O-methacryloyl-D-galactose) (100
mg) with succinic anhydride (20, 40, 60 and 90 mg, respectively) in 20 mL of dry dimethyl
formaldehyde (Scheme 4). The mixtures were stirred at ambient temperature to form a
homogeneous solution, followed by dropwise addition of 5 mL of dry pyridine. After 2 days,
the solutions were dialyzed (10 kDa tubing) against 50% ethanoic water for 1 day followed
by absolute ethanol for 1 day, with solvent changes every 6 hrs to remove the dimethyl
formaldehyde, pyridine, and other small molecule impurities. Lyophilization of the resulting
solution led to the desired sugar multi-arm polymers with increasing substitution degrees of
carboxylic acids.
2.2.4 Synthesis of JS-K and JS-K analogues
Synthesis of JS-K, O2-(2, 4-Dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl]
diazen-1ium-1, 2-diolate: The synthetic route is depicted in Scheme 5. Briefly, to a 250 mL
round bottom flask were added 2.10 g of compound 1 (5.09 mmol) and 130 mL of ethyl
acetate. After the mixture was cooled to 0 °C, 11.5 mL of concentrated HCl was added
dropwise. The reaction was allowed to warm to ambient temperature and stirred overnight.
The resulting suspension was filtered and the yellow solid was washed with 100 mL of ethyl
acetate and then dried under reduced pressure. The desired compound 2 was obtained
without further purification, and the molecular structure was verified by 1H-NMR, 13C-
NMR and high resolution mass spectrometry (HRMS).
Subsequently, compound 2 (0.132 g, 0.38 mmol) and ethyl chloroformate (56 μL, 0.57
mmol) were combined in 4 mL of dry THF. After cooling to 0 °C, triethylamine (1.14
mmol) was added. The reaction was kept at 0 °C for 10 minutes and then stirred at ambient
temperature for 3 h or until TLC indicated complete consumption of starting material 2. The
mixture was diluted with 10 mL of THF, and the organic phase was washed with water,
saturated sodium bicarbonate solution and brine, and dried over sodium sulfate. Evaporation
of the solvent under reduced pressure followed by purification of the residue using silica gel
flash chromatography with 1:1 ethyl acetate:hexanes as eluents led to the desired compound
JS-K (compound 3), and the molecular structure was verified by 1H-NMR, 13C-NMR and
HRMS.
Synthesis of JS-K analogue 2, O2-(2,4-Dinitrophenyl) 1-[[4-(2-hydroxy)ethyl]-3-
methylpiperazin-1-yl]diazen-1-ium-1,2-diolate: The JS-K analogue NO2 (compound 4)
was synthesized according to Chakrapani's procedure with modifications [28] (Scheme 6).
Briefly, a solution of 1-(butyloxycarbonyl) homopiperazine (10 g, 50 mmol) in methanol (2
mL) was treated with 25% w/v methanolic sodium methoxide (9.3 mL) and ether (10 mL).
The resulting solution was charged with 60 psi NO and stirred at ambient temperature for 24
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hours. A white precipitate was filtered, washed with ether, and dried under reduced pressure
to afford sodium 1-[(4-tert-butoxycarbonyl) homopiperazin-1-yl] diazen-1-ium-1, 2-diolate,
and the molecular structure was verified by 1H-NMR, 13C-NMR and HRMS.
Synthesis of JS-K analogue 1, O2-(2,4-Dinitrophenyl) 1-{[4-(2-(2-hydroxyethoxy))ethyl]
piperazin-1-yl}diazen-1-ium-1,2-diolate: The JS-K analogue NO1 (compound 5) was
synthesized based on the synthesis of analogue 2 using 1-[2-(2-hydroxyethoxy)ethyl]
piperazine (5.0 g, 27.3 mmol) as the starting material (Scheme 6). The resulting crude
compound was purified through chromatography on silica gel using 1:1 ethyl
acetate:hexanes as eluents to afford the desired compound, and the molecular structure was
verified by 1H-NMR, 13C-NMR and HRMS.
2.2.5 Synthesis of multi-arm poly-(6-O-methacryloyl-D-galactose)-acid-NO 1 conjugate
(multi-arm polymer-JSK analogue 1 conjugate): Multi-arm poly-(6-O-methacryloyl-D-
galactose)-60% (50 mg) was dissolved in 25 mL of DMF: dd H2O (25:1 v/v). After a
homogeneous solution formed, EDCI·HCl (1.5 eq) and HOBt·H2O (1.5 eq) were added and
the temperature was kept at 0 °C. After 5 minutes, JS-K analogue NO1 (1.0 eq) was added.
The reaction proceeded at 0 °C for 30 minutes and then at ambient temperature overnight
under argon. The resulting solution was dialyzed against 50% v/v ethanol in water for 12 hrs
and then absolute ethanol for 12 hrs using 10 kDa dialysis tubing (Scheme 7). Removal of
the solvent under reduced pressure led to the desired conjugate, and the molecular structure
and drug loading degree were determined by 1H-NMR.
2.3 Characterization
2.3.1 Size exclusion chromatography—The molecular weights and polydispersity
index (PDI) of the multi-arm polymers D,L-PLA-block-PAIpGP were determined using an
EZStart 7.4 software and a Shimadzu 2010CHT system equipped with an RID-10A
refractive index detector and a TSK gel multipore Hx-M 7.8×30 cm column. The mobile
phase contained 10-mM LiCl in DMF (0.8 mL/min). The calibration curve was generated
using polystyrene standards ranging from 1,180 to 339,500 g/mol. After deprotection, the
resulting multi-arm poly-(6-O-methacryloyl-D-galactose) was highly soluble in methanol,
water, DMF and DMSO. The molecular weights of the acid multi-arm polymers were
determined by SEC using the same condition except that the system was calibrated using
polyethylene glycol (PEG) standards ranging from 3,070 to 66,100 g/mol (Scientific
Polymer Products, Inc). The degree of substitution was determined by 1H-NMR in MeOD,
based on the ratio of the methylene protons of the acid groups to the protons of the sugar
groups.
2.3.2 NMR—The molecular structures of the MADIX/RAFT agent, 4-arm polymer, acid
derivatives of the 4-arm polymer, JS-K and its analogues (NO1 and NO2), and the 4-arm
polymer-NO conjugate (sugar-NO1) were determined by 1H-NMR, 13C-NMR and HRMS.
The substitution degrees of the acid on the sugar multi-arm polymer were determined by 1H-
NMR based on the ratio of the methylene protons of the acid groups to the protons of the
sugar groups. The following sugar acid polymers have been made successfully: sugar-20%
acid, sugar-40% acid, sugar-60% acid, sugar-90% acid. In addition, the substitution degree
of NO1 prodrug on the sugar-NO1 conjugate was also determined by 1H-NMR.
2.3.3 Solubility—The water solubilities of multi-arm poly-(6-O-methacryloyl-D-
galactose) and its acid-modified derivatives were measured in 1× PBS (pH 7.4) at 37 °C.
The solutions were kept under this condition and monitored for precipitation for 24 hrs.
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2.3.4 Viscosity—The viscosity parameters were measured using a Stabinger viscometer
(SVM 3000, Anton Paar, USA). A series of sugar multi-arm polymer samples with or
without acid modification (20%, 40%, 60% and 90% wt/wt) were prepared by dissolving the
polymers in dd H2O at three concentrations including: 1.0 mg/mL, 3.0 mg/mL and 10.0 mg/
mL. The viscosity measurements are reported in Figure 4.
2.4 Cytotoxicity
Cell growth inhibition was determined in 96-well plates (3,000 cells/well in 100 μL, 12
replicates/sample). Drug or conjugate solutions were applied after 24 hrs, and 72 hrs post-
addition, resazurin blue in 10 μL of PBS was applied to each well (final concentration 5
μM). After 4 hrs, well fluorescence was measured (ex/em 560/590) (SpectraMax Gemini,
Molecular Devices), and the IC50 concentration determined as the midpoint between drug-
free medium (positive) and cell-free (negative) controls.
2.5 Nitric oxide release
To determine the release half-life of nitric oxide from JS-K, NO1, NO2 and sugar-NO1,
MDA-1986 cells were seeded in 96-well plates 24 hours prior to drug treatment (100 μL/
well). On the following day, cells were treated with 20 μM of either one of the nitric oxide
prodrugs (NO1, NO2 or JS-K) or the multi-arm polymer based nitric oxide prodrug
conjugate number 1 (sugar-NO1). Fifty microliters of cell culture media were collected from
each plate at 10 minutes, 2, 7, 22, 48 and 96 hours, post treatment to determine the nitrite
content (N=5). The Griess reaction was performed according to the manufacturer's
suggestions. The fluorescence intensity was measured between 520 and 550 nm using a
fluorescence microplate reader. The nitrite concentration and the corresponding nitrite oxide
levels were determined using the nitrite standard curve previously generated.
2.6 Tumor model and efficacy
The MDA-1986 human head and neck squamous cell carcinoma cells were prepared in PBS
at a concentration of 2 ×107 cells/mL. Female nude mice were anesthetized with 1.5%
isoflurane in 50% O2:air mixture, and 50 μL of cell solution was injected into the sub-
mucosa of the mice using a 30-ga needle.
This xenograft model has been used in our laboratory to evaluate a hyaluronan-based drug
delivery system [15]. Typically, the primary tumors with sizes between 5 to 150 mm3 were
observed on the cheeks 2 weeks after cell implantation. The tumor growth was monitored 2
to 3 times weekly by measurement with a digital caliper in two perpendicular dimensions,
and the tumor volume was calculated using the equation: tumor volume = 0.52 × (width)2 ×
(length). Animals were euthanized when their tumor size reached 1000 mm3 or the body
score index dropped below 2 [29].
Animals bearing head and neck tumors were randomly divided into 3 groups, including
Sugar NO1 s.c. group (N=11), JS-K i.v. group (N=7) and untreated control group (N=8).
The treatments were administered subcutaneously next to the tumor three week after tumor
cell implantation, at a dose of 10 mg/kg on the basis of NO prodrugs.
3. Results
3.1 Synthesis
The yield of the MADIX/RAFT polymerization reaction mediated by xanthates was ca.
90%. The NMR results demonstrated that the satisfactory conversion and polymerization
were obtained when the reaction was allowed to proceed for 8 to 12 hrs. After deprotection,
the resulting sugar multi-arm polymer is highly soluble in water and organic solvents,
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including CH2Cl2, CHCl3, DMF and THF. The sugar multi-arm polymers were further
modified using succinic anhydride to yield multi-arm polymers with increasing degrees (20,
40, 60 and 90%) of terminal carboxylic acid groups on the polymer arms.
The nitric oxide prodrug JS-K and its two analogues were successfully synthesized; the
yields of the reactions are reported in NMR 3.3.2. The analogue number 1, O2-(2,4-
dinitrophenyl) 1-[4-(2-hydroxy)ethyl]-3-methylpiperazin-1-yl]diazen-1-ium-1,2-diolate, was
selected to be further conjugated onto the sugar multi-arm polymer with 60% acid
substitution, resulting in the formation of a multi-arm polymer-NO1 conjugate. The
substitution degree of NO1 prodrug on the conjugate was determined to be approximately 12
% (wt/wt) based on the ratio of the aromatic protons of the NO1 prodrug to the protons of
the repeating units of the multi-arm polymer backbone.
3.2 Characterization
3.2.1 Size exclusion chromatography—The molecular weight of the multi-arm poly-
(1,2:3,4-di-O-isopropylidene-6-O-methacryloyl-α-D-galactopyranose) synthesized was
determined by SEC using polystyrene polymers as standards. The number average
molecular weight, Mn, and the polydispersity index, PDI, were determined to be 73,292 g/
mol and 1.13, respectively (Figure 2). After the removal of the isopropylidene protecting
groups within the multi-arm polymer, the molecular weight of the resulting multi-arm poly-
(6-O-methacryloyl-D-galactose) was determined by SEC under the same condition except
that PEG polymers were used as standards. The Mn and PDI were determined to be 45,460
g/mol and 1.20, respectively (Figure 2). After the modification of the multi-arm poly-(6-O-
methacryloyl-D-galactose) with succinic anhydride, the resulting acid derivatives of the
polymer were analyzed by SEC and their molecular weights and PDIs were reported in
Table 1.
3.2.2 NMR—The molecular structures of JS-K and its two analogues were determined
by 1H-NMR, 13C-NMR and HRMS. The substitution degrees of the carboxylic acid groups
on the arms of the sugar multi-arm polymer were determined by 1H-NMR for all four acid
derivatives of the polymer, based on the ratios of the methylene protons of the acid groups to
the protons of the sugar side chains. In addition, the substitution degree of NO1 on the sugar
multi-arm polymer backbone was also determined by 1H-NMR. The chemical shifts of all
NMR spectra were measured as follows.
Synthesis of MADIX/RAFT agent
Bromo intermediate: 4.89 g of the desired compound was obtained with a yield of 72%. 1H-
NMR (CDCl3, 400 MHz) δ: 1.85 (d, 12 H, J = 7.0), 4.22–4.23 (m, 4H), 4.33–4.39 (m, 4H),
4.41 (q, 4 H, J = 7.0). The chemical shifts are consistent with the structure and no impurities
or unknown peaks were observed.
MADIX/RAFT compound: The desired compound was obtained with a yield of 100%. 1H-
NMR (CDCl3, 400 MHz) δ: 1.44 (t, 12 H, J = 7.0), 1.60 (d, 12 H, J = 7.2), 4.12–4.22 (m,
8H), 4.44 (q, 4 H, J = 7.2), 4.66 (q, 8 H, J = 7.0). The peak shifts were consistent with the
structure and suggested that the compound was pure.
1,2;3,4-di-O-isopropylidene-6-O-acryloyl-α-D-galactopyranose (AIpGP): The desired
compound was obtained with a yield of 94%. 1H-NMR (CDCl3, 400 MHz) δ: 1.35 (s, 3H),
1.37 (s, 3H), 1.48 (s, 3H), 1.53 (s, 3H), 4.07–4.11(m, 1 H), 4.27–4.32 (m, 2 H), 4.35 (dd, 1
H, J = 2.5, 5.0), 4.41 (dd, 1 H, J = 4.7, 11.6), 4.65 (dd, 1 H, J = 2.5, 7.9), 5.56 (d, 1 H, J =
5.0), 5.85 (dd, 1 H, J = 1.4, 10.4), 6.19 (dd, 1 H, J = 1.4, 10.4), 6.46 (dd, 1 H, J = 1.4, 17.4).
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The peak shifts were consistent with the structure and suggested that the compound was
pure.
Synthesis of multi-arm polymers
Multi-arm poly-(1,2:3,4-di-O-isopropylidene-6-O-methacryloyl-α-D-
galactopyranose): 1H-NMR (D2O, 400 MHz) δ: 1.29–2.05 (brs, 1 H), 2.17–2.74 (brs, 2 H),
3.45–4.17 (brs, 6H), 5.26 (brs, 1 H).
Multi-arm poly-(6-O-methacryloyl-D-galactose): 1H-NMR (D2O, 400 MHz) δ: 1.29–2.05
(brs, 1 H), 2.17–2.74 (brs, 2 H), 3.45–4.17 (brs, 6H), 5.26 (brs, 1 H).
Synthesis of JS-K and its analogues
Boc-Hydrazine: The desired compound was obtained as a white solid with a yield of
54%. 1H-NMR (CDCl3, 400 MHz): δ = 1.81–1.87 (m, 1H), 1.95 (brs, 1H), 2.06–2.12 (m,
2H), 2.27–2.33 (m, 1H), 2.88 (dd, J = 10.2, 7.8 Hz, 1H), 3.55 (ddd, J = 16.6, 10.8, 5.9 Hz,
1H), 3.68–3.73(m, 1H), 3.85 (dt, J = 8.0, 3.6 Hz, 1H), 4.23–4.25 (m, 1H), 7.16 (d, J = 9.6
Hz, 1H). 8.17 (dd, J =9.6, 2.7 Hz, 1H), 8.66 (d, J = 2.7 Hz, 1H). The data was consistent
with that reported previously.
Compound 1: The desired compound was obtained as a yellow solid with a yield of
53%. 1H-NMR (CDCl3, 400 MHz): δ = 1.81–1.87 (m, 1H), 1.95 (brs, 1H), 2.06–2.12 (m,
2H), 2.27–2.33 (m, 1H), 2.88 (dd, J = 10.2, 7.8 Hz, 1H), 3.55 (ddd, J = 16.6, 10.8, 5.9 Hz,
1H), 3.68–3.73(m, 1H), 3.85 (dt, J = 8.0, 3.6 Hz, 1H), 4.23–4.25 (m, 1H), 7.16 (d, J = 9.6
Hz, 1H). 8.17 (dd, J =9.6, 2.7 Hz, 1H), 8.66 (d, J = 2.7 Hz, 1H). The data were consistent
with that reported previously.
Compound 2: The desired compound was obtained as a yellow solid with a yield of
96%. 1H-NMR (DMSO-d6, 400 MHz): δ = 3.35 (brs, 4 H), 3.92 (brs, 4H), 7.98 (d, J = 9.3
Hz, 1H), 8.58 (dd, J = 9.3 Hz, 2.7 Hz, 1H), 8.89 (d, J = 2.4 Hz, 1H), 9.64 (brs, 2H). 13C-
NMR (DMSO-d6, 100 MHz): δ = 41.8, 47.4, 118.8, 122.3, 130.2, 137.4, 142.8, 153.0.
HRMS (ESI) calculated for C10H13N6O6 (M + H)+: 313.0897; Found: 313.0895.
Compound 3: The desired compound was obtained as a yellow solid with a yield of
90%. 1H-NMR (CDCl3, 400 MHz): δ = 1.30 (t, J = 5.7 Hz, 3H), 3.29 (brs, 4 H), 3.71 (t, J =
5.2 Hz, 4H), 4.20 (q, J = 14.2, 7.1 Hz, 2H), 7.14 (d, J = 9.3 Hz, 1H). 8.31 (dd, J = 9.2 Hz, 2.7
Hz, 1H), 8.90 (d, J = 2.7 Hz, 1H); 13C-NMR (CDCl3, 100 MHz): δ = 14.6, 42.2, 50.5, 62.1,
117.7, 122.2, 129.1, 137.3, 142.4, 153.7, 155.0. HRMS (ESI) calculated for C13H16N6O8 (M
+ Na)+ : 407.0927; Found: 407.0932.
Compound 4: The desired compound was obtained as a yellow solid with a yield of
64%. 1H-NMR (CDCl3, 400 MHz): δ = 2.42 (brs, 1H), 2.66 (t, J = 5.2 Hz, 2H), 2.78 (t, J =
4.9 Hz, 4H), 3.68–3.73 (m, 6H), 7.69 (d, J = 9.3 Hz, 1H). 8.48 (dd, J = 9.2, 2.5 Hz, 1H), 8.89
(d, J =2.5 Hz, 1H); 13C-NMR (CDCl3, 100 MHz): δ = 50.6, 51.2, 58.1, 58.7, 117.6, 122.2,
129.1, 137.4, 142.7, 153.9. HRMS (ESI) calculated for C12H17N6O7 (M + H)+: 357.1159;
Found: 357.1144.
Compound 5: The desired compound was obtained as a yellow solid with a yield of
68%. 1H-NMR (CDCl3, 400 MHz): δ = 1.69 (brs, 1H), 2.70 (t, J = 5.3 Hz, 2H), 2.80 (t, J =
5.1 Hz, 4H), 3.63–3.66 (m, 2H), 3.69–3.75 (m, 8H), 7.68 (d, J = 9.3 Hz, 1H). 8.47 (dd, J =
9.2, 2.7 Hz, 1H), 8.90 (d, J = 2.7 Hz, 1H); 13C-NMR (CDCl3, 100 MHz): δ = 50.3, 51.5,
57.0, 61.9, 68.0, 72.3, 117.6, 122.2, 129.1, 137.2, 142.3, 153.9. HRMS (ESI) calculated for
C14H21N6O8 (M + H)+: 401.1421; Found: 401.1413.
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Synthesis of multi-arm polymer-NO conjugate
Multi-arm poly-(6-O-methacryloyl-D-galactose)-acid-NO1 conjugate: The desired
compound was obtained as a yellow solid with a yield of 29%. 1H-NMR (CDCl3, 400
MHz): δ = 1.81–1.87 (m, 1H), 1.95 (brs, 1H), 2.06–2.12 (m, 2H), 2.27–2.33 (m, 1H), 2.88
(dd, J = 10.2, 7.8 Hz, 1H), 3.55 (ddd, J = 16.6, 10.8, 5.9 Hz, 1H), 3.68–3.73(m, 1H), 3.85
(dt, J = 8.0, 3.6 Hz, 1H), 4.23–4.25 (m, 1H), 7.16 (d, J = 9.6 Hz, 1H). 8.17 (dd, J =9.6, 2.7
Hz, 1H), 8.66 (d, J = 2.7 Hz, 1H).
3.2.3 Solubility—The solubilities of sugar polymer poly-(6-O-methacryloyl-D-galactose)
and its acid-modified derivatives were determined in pH 7.4 PBS at 37 °C (Figure 3). The
result suggested a linear increase in the solubility with increasing degrees of acid
substitution from 0–60% wt (R2=0.998). In addition, the intrinsic solubility of the polymer
with 90% acid substitution did not further increase and it appeared to exhibit a similar
solubility as the polymer with 60% acid substitution.
3.2.4 Viscosity—The viscosities of sugar multi-arm polymer, poly-(6-O-methacryloyl-D-
galactose), and its acid-modified derivatives (sugar polymers with 20%, 40%, 60% and 90%
acid substitution) were determined in dd H2O at three increasing concentrations (1.0, 3.0 and
10.0 mg/mL) (Figure 4). The polymers demonstrated low viscosities, merely 5–10% higher
than pure H2O, regardless of the percent of the acid substitution. Furthermore, the viscosities
of various polymers with different degrees of acid substitution appeared to increase with
increasing polymer concentrations from 1.0 to 10.0 mg/mL.
3.3 Cytotoxicity
The cytotoxicity of nitric oxide-releasing prodrugs and polymer-based conjugates was
determined in a human head and neck cancer cell line, MDA-1986, and human breast cancer
cell lines, MDA-MB-468 and MDA-MB-231. The IC50 values of NO1, NO2, JS-K and
sugar-NO1 are reported in Table 2.
3.4 Nitric oxide release in vitro
The release kinetics of nitric oxide prodrugs were determined in cell culture (DMEM with
10% bovine serum albumin and 1% L-glutamine) using human HNSCC cell line,
MDA-1986. The concentration of nitrite, the breakdown product of gaseous nitric oxide,
was measured using Griess assay as an indirect measurement of nitric oxide concentration in
cell culture media. The assay is based on the reaction between sulfanilamide, N-1-
napthyethylenediamine dihydrochloride and nitrite, under acidic conditions to produce a
fluorescent azo compound. A nitrite calibration curve (R2=0.99) was generated under the
same condition using a series of nitrite solutions (0, 1.56, 3.13, 6.25, 12.5, 25, 50, and 100
μM).
All three nitric oxide prodrugs, NO1, NO2 and JS-K, as well as the sugar-NO1 conjugate,
produced nitric oxide in a sustained manner, generating half-lives of 6, 7, 3 and 10 hours,
respectively (Figure 5).
3.5 Treatment
We have established an orthotopic rodent xenograft model of human HNSCC with rapid and
sustained tumor growth in our previous study [15]. Animals in either the control group or
the JS-K i.v. treatment group had tumors with a size of approximately 1000 mm3, five or
seven weeks after tumor cell implantation, respectively (Figure 6A). In comparison, the
animals treated with sugar-NO1 developed a tumor of an average size of approximately 200
mm3 within the same time frame. Additionally, 32% of animals in the sugar-NO1 group
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survived the study (21 weeks post-tumor cell injection), and two mice had a complete
response (defined as no evidence of residual disease) within 14 weeks (Figure 6A). On the
contrary, 100% of the control or JS-K treated animals were euthanized within 7 weeks either
due to the tumor size exceeding 1000 mm3 or necrosis of the injection site on the tail.
Further, HNSCC tumor progression was delayed by nearly 7 weeks on average after s.c.
sugar-NO1 therapy, and the survival rate was significantly extended relative to the control
group (ρ < 0.001, Figure 6B). The disease condition of each individual animal in the control
or treated groups is reported in Table 3. CR=Complete Response (no gross evidence of
tumor); PR=Partial Response (>30% reduction); SD=Stable Disease (neither PR nor PD
criteria met); PD=Progressive Disease (<30% tumor growth). Mice with an ulcerated tumor
that were euthanized before the end of the study were excluded from this analysis.
4. Discussion
Xanthate-mediated living radical polymerization using an MADIX/RAFT agent has been
proven to successfully synthesize a number of novel polymeric materials, including star-
shaped polymers [26], functional diblock [30] and triblock copolymers [31], which could be
introduced into the fields of chemical and pharmaceutical industries as additives,
emulsifiers, surface coating materials as well as potential drug delivery vehicles.
In this study, we successfully synthesized a 4-arm branched polymer grafted with sugar
moieties. The spherical multi-arm polymer has a compact structure, low polydispersity index
and large surface area, making it an ideal candidate for drug delivery applications. In
addition, the presence of a number of sugar molecules on the polymer chains effectively
converts a hydrophobic synthetic polymer into a highly water-soluble and biocompatible
polymer due to the ease of degradation of the sugar braches by the naturally-occurring
enzymes in vivo. Although the polystyrene backbone is not biodegradable, the arms are
connected to the core via esters subject to hydrolytic decomposition in vivo. The liberated
polystyrene arms are below the renal exclusion limit and should clear from the systemic
circulation. These unique properties of the polymer may be advantageous because they
could be readily translated into practical benefits, including: the elimination of the presence
of any organic solvents in its aqueous solution; the satisfactory injectability of even the
highly concentrated polymer solution due to its extremely low viscosity; and the low toxicity
compared to other synthetic polymers, such as PAMAM dendrimers, due to its
biodegradability and biocompatibility.
The intrinsic solubilities of the acid multi-arm polymers was highly correlated with
increasing degrees of acid substitution (R2=0.998). As the degree of acid substitution
increased (0, 20, 40 and 60%), the surface charge density of the polymers as well as the
average number of hydrogen bonds between the carboxylic acid groups of the polymer and
the water molecules also increased, leading to favorable enthalpic interactions between the
polymer and the surrounding water molecules along with the desired intra- and inter-
molecular electrostatic repulsions within the multi-arm polymer itself [32, 33]. The linear
solubility characteristic of the acid multi-arm polymers could be further applied to other
natural, semi-synthetic or synthetic polymers, promoting and possibly predicting the
solubilities of their acid-modified derivatives. As the degree of acid substitution increased
beyond 60%, the solubility of the resulting acid polymers plateaued and did not further
increase. It is likely due to the possible crosslinking between the highly abundant carboxylic
acid groups and the hydroxyl groups of the sugar molecules, reducing the flexibility of the
polymer chains and restricting the overall dynamics of the polymer structure.
Low viscosity is crucial for local injectables, since injection volumes are much smaller than
intravenous treatments and smaller bore needles are desired for patient comfort. High
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viscosity is usually associated with low injectability and great discomfort at the injection
site. The sugar multi-arm polymer our laboratory synthesized demonstrated extremely low
intrinsic viscosity at 1% w/v compared to other polymers for local injection, such as
hyaluronan [34], resulting in a smooth delivery of high doses of therapeutics via a relatively
small volume of injection.
In addition to the synthesis of this novel multi-arm polymer nanocarrier, the synthesis,
characterization and in vivo effectiveness of two new nitric-oxide releasing prodrugs, NO1
and NO2, are also reported. Since the emergence of JS-K, a glutathione s-transferase (GST)-
activated nitric oxide prodrug, the underlying mechanisms regulating nitric oxide-induced
cell death have been extensively investigated. Up to date, multiple signaling pathways have
been discovered to be involved in promoting the death of cancer cells, suggesting NO is
likely to mediate cell proliferation via multiple complex pathways. Sang et al. proposed that
nitric oxide donating prodrugs may trigger the apoptosis of gastric cancer cells via the
inactivation of AKT, a serine/threonine protein kinase, resulting in the dysregulation of cell
cycle-associated proteins, and thus leading to G0/G1 arrest and the corresponding cell
growth inhibition [35]. According to a study conducted by Mijatovic et al., nitric oxide also
can induce apoptosis of melanoma cells via a TRAIL-mediated pathway, in which cells are
sensitized to TRAIL and the expression of inducible nitric oxide synthase (iNOS) is altered
[36]. Furthermore, Kim et al. demonstrated that nitric oxide-induced apoptosis of colon
cancer cells is associated with caspases activation and it may be attributed to the
downregulation of the anti-apoptotic Bcl-2 oncoprotein, along with the activation of p53
signaling pathway [37].
Due to the complex nature of NO mediated cell death, it is less likely for cancer cells to
develop a series of acquired resistance mechanisms against all governing pathways.
Therefore, we sought to design a long-acting, nitric oxide-donating nanocarrier that could be
given as locoregional chemotherapy for locally advanced cancers, including head and neck
cancer and breast cancer, to generate cytotoxic nitric oxide molecules over time in a
sustained pattern. The in vitro nitric oxide release data elucidated that the newly synthesized
nitric oxide prodrugs, NO1 and NO2, both demonstrated longer nitric oxide release half
lives in head and neck cancer cells. Additionally, the sugar-NO1 nanoconjugate exhibited
the longest release half-life, which was 2.3-fold longer than the model NO-releasing drug,
JS-K. Therefore, if the in vitro drug release kinetics correctly represents the in vivo
conditions, the sugar-NO1 conjugate may be a promising candidate for the controlled release
of nitric oxide in tumor-bearing animals. According to a study conducted by Azizzadeh et
al., NO-producing prodrugs with a longer release half life may be more potent inhibitors of
DNA synthesis and mitotic activity in the S-phase compared to short-lived NO-prodrugs
[38].
Compared to JS-K, both unbound NO1 and NO2 had slightly higher IC50 values in
MDA-1986 cells, whereas, they both showed higher in vitro toxicity in MDA-MB-468 cells.
Even though the carrier-bound sugar-NO1 conjugate had higher IC50 values than the
standard JS-K, according to our previous studies using hyaluronan-cisplatin and hyaluronan-
doxorubicin conjugates, the subcutaneously administered, sustained nitric oxide-releasing
platform may provide additional benefits including: modified drug pharmacokinetics by
avoiding the potentially harmful Cmax; reduced systemic toxicities due to limited drug
exposure within the circulatory system and highly perfused, toxin-susceptible organs
(kidneys, liver and heart); and improved local disease control via localized delivery of
highly concentrated NO therapy [14–18].
In the following in vivo evaluation of the anti-cancer efficacy of the sugar-NO1 therapy, we
demonstrated that the subcutaneously injected conjugate (10 mg/kg) significantly improved
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the tumor inhibition in HNSCC xenografts, extending the average life span of the animals by
7 weeks, which was one third the length of the timeframe of the study. In contrast, the
intravenous therapy of JS-K at an equivalent dose only resulted in a slight regression of
tumor growth and a very limited increase of animals' survival rate. In addition, the localized
injection also provided benefit in terms of tumor response, compared to the i.v. therapy,
resulting in 25% of complete response and 37.5% of partial response. Unfortunately the
entire group of animals received i.v. therapy developed progressive disease and none of
them responded to the JS-K treatment. Furthermore, one third of the animals in the JS-K i.v.
group experienced necrosis and inflammation of the injection site on their tails, which may
be attributed to the toxicity of JS-K.
5. Conclusions
We have developed the first locoregional nitric oxide delivery platform for treating locally
advanced head and neck cancer using multi-arm polymer nanocarriers. This strategy could
be adapted to other types of cancers, including breast cancer and prostate cancer, which
were shown to be responsive to JS-K therapy [39–42]. Furthermore, recent investigations
have discovered that nitric oxide may be involved in the reversal of cisplatin resistance in
head and neck cancer [43], ovarian cancer [44, 45] and lung cancer [46], via mechanisms of
survivin modulation, depletion of cellular thiols, and inhibition of Bcl-2 ubiquitination,
respectively. Similar re-sensitizing effects of nitric oxide were also reported in the reversal
of doxorubicin chemo-resistance in human colon cancer [47]. Taken together, this NO-
eluting nanocarrier could either be utilized as a single treatment for JS-K responsive cancers,
or incorporated into a combination therapy regimen to revert drug-induced chemo-
resistance. Our ongoing studies will focus on optimizing the in vitro and in vivo properties
of this type of nitric oxide releasing nanocarriers, laying the foundation for future
translational study, to develop a safety and effective nitric oxide formulation for treating
cisplatin and doxorubicin resistant cancers.
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NO1 JS-K analogue 1, O2-(2,4-Dinitrophenyl) 1-{[4-(2-(2-
hydroxyethoxy))ethyl] piperazin-1-yl} diazen-1-ium-1,2-diolate
NO2 JS-K analogue 2, O2-(2,4-Dinitrophenyl) 1-{[4-(2-hydroxy)ethyl]-3-
methylpiperazin-1-yl}diazen-1-ium-1,2-diolate
Sugar-NO1 Poly-(6-O-methacryloyl-D-galactose)-nitric oxide prodrug analog 1
conjugate
GST glutathione s-transferase
iNOS inducible nitric oxide synthase
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Structure of a 4-arm sugar polymer
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(A) 1H-NMR spectra and (B) GPC traces of multi-arm poly-(1,2:3,4-di-O-isopropylidene-6-
O-methacryloyl-α-D-galactopyranose) (Mn=73,292 Da, PDI=1.13) and multi-arm poly-(6-
O-methacryloyl-D-galactose)) (Mn=45,460 Da, PDI=1.20).
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Solubility of sugar multi-arm polymer and its acid derivatives. Solubility determined in pH
7.4 PBS at 37 °C.
Duan et al. Page 18














Viscosity measurement of sugar multi-arm polymer and sugar-acid polymers.
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In vitro production of nitric oxide by NO1, NO2, JS-K, and sugar-NO1 (20 μM starting
concentration on NO basis). The release studies were conducted in DMEM in the presence
of MDA-1986 cells. The release half-lives were determined to be 6, 7, 3 and 10 hours, for
NO1, NO2, JS-K and sugar-NO1, respectively.
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A) Size measurement of head and neck tumors and B) survival rate of the animals.
Treatment groups include: Sugar-NO1 (s.c., 10 mg/kg dose on NO1 basis, N=11), JS-K (i.v.
10 mg/kg dose, N=7) and treatment-free control (N=8). Errors were reported in standard
error of the mean.
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Synthesis of MADIX/RAFT agent
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Synthesis of 4-arm sugar polymers by MADIX/RAFT polymerization
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Modification of multi-arm poly-(6-O-methacryloyl-D-galactose) with succinic anhydride
resulted in polymers with increasing degree of acid substitution (20, 40, 60 and 90% wt/wt).
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Synthesis of JS-K analogues
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Synthesis of acid sugar multi-arm polymer-JS-K analogue NO1 conjugate (sugar-NO1)
Duan et al. Page 28

























Duan et al. Page 29
Table 1
Molecular weights and PDIs of acid derivatives of sugar multi-arm polymer.
Acid% Mtheo, g/mol Mn,GPC*, g/mol PDI
0 54,610 45,460 1.20
20 54,610 45,890 1.19
40 63,640 54,390 1.17
60 72,730 60,110 1.21
90 86,370 75,100 1.15
*
Standard: PEG; mobile phase: DMF (10 mM LiCl); flow rate: 1.0 mL/min.
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Table 2
IC50 values of NO prodrugs (NO1, NO2 and JS-K) and multi-arm polymer-NO1 conjugates.
Prodrugs/conjugates IC50: MDA-1986 IC50: MDA-MB-468 IC50: MDA-MB-231
NO1 32 μM 26 μM 32 μM
NO2 57 μM 27 μM –
JS-K 16 μM 42 μM –
Sugar-NOl 86 μM 67 μM 120 μM
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Table 3
Disease condition of tumor bearing mice in control, i.v. JS-K and s.c. Sugar-NO1 treatment groups. Tumor
response was reported based on modified RECIST criteria.
Treatment Group Animal No.l Animal No.2 Animal No.3 Animal No.4 Animal No.5 Animal No.6 Animal No.7 Animal No.8
Sugar NO 1 s.c. PR PD CR PD PD PR CR PR
JS-K i.v. PD Necrosis PD PD Necrosis PD – –
Control PD PD PD PD PD PD PD –
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